Blog
RSS FeedPosted by Michael Wonder on 01 Apr 2026
Injection for more than a million people to help prevent heart attacks and strokes recommended
1 April 2026 - People who have had a heart attack, stroke, or serious circulation problem in their legs, and who ...
Posted by Michael Wonder on 20 Mar 2026
Public summary documents (first time decisions not to recommend and deferrals) – November 2025 PBAC meeting
20 March 2026 - The Public Summary Documents (first time decisions not to recommend and deferrals) from the November 2025 PBAC ...
Posted by Michael Wonder on 12 Mar 2026
500,000 eligible to benefit from new non-hormonal treatment for hot flushes caused by menopause
11 March 2026 - A new treatment option for menopausal hot flushes and night sweats can be used in the NHS ...
Posted by Michael Wonder on 06 Mar 2026
Public summary documents – November 2025 PBAC meeting
6 March 2026 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the November 2025 PBAC ...
Posted by Michael Wonder on 04 Mar 2026
Problems in study implementation: It often affects patient reported outcomes.
2 March 2026 - Patient-reported outcomes are of great importance for the evaluation of new drugs. However, these outcomes are repeatedly ...
Posted by Michael Wonder on 03 Mar 2026
Alnylam receives positive recommendation from Canada's Drug Agency for the public reimbursement of Amvuttra (vutrisiran injection), the first and only RNAi therapeutic for the treatment of cardiomyopathy in adult patients with ATTR amyloidosis
2 March 2026 - Alnylam Canada is pleased to announce it has received a positive recommendation from Canada's Drug Agency for ...
Posted by Michael Wonder on 24 Feb 2026
First treatment for vitiligo recommended by NICE for NHS use, bringing hope to over 80,000 people
24 February 2026 - For the first time, NICE has recommended a medicine that effectively treats the underlying cause of devastating ...
Posted by Michael Wonder on 21 Feb 2026
Canada's public drug plans shouldn't cover new Alzheimer's drug, agency says
19 February 2026 - Lecanemab, also known as Leqembi, is approved to treat mild cognitive impairment, early Alzheimer's. ...
Posted by Michael Wonder on 18 Feb 2026
NICE recommends first ever disease modifying treatment for ARG1 deficiency
17 February 2026 - NICE has recommended the first disease modifying treatment for arginase 1 deficiency (ARG1-D), an ultra-rare, inherited and ...
Posted by Michael Wonder on 09 Feb 2026
SMC - February 2026 decisions
9 February 2026 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice ...
Posted by Michael Wonder on 02 Feb 2026
Donanemab in early Alzheimer's disease: important questions remain unanswered
30 January 2026 - For the treatment of Alzheimer's disease, it is crucial to distinguish between those with mild cognitive ...
Posted by Michael Wonder on 31 Jan 2026
Cancer patients gain new hope as Keytruda treatment recommended for subsidy under PBS
31 January 2026 - Lifesaving treatment for cancers that now costs tens of thousands of dollars is set to be cut ...
Posted by Michael Wonder on 30 Jan 2026
Recommendations made by the PBAC – December 2025 intracycle meeting
30 January 2026 - The recommendations from the December 2025 PBAC intracycle meeting are now available. ...
Posted by Michael Wonder on 28 Jan 2026
New hope for people with breathing condition, COPD, as NICE approves innovative treatment
26 January 2026 - Almost 30,000 people in England with a respiratory disease called COPD (chronic obstructive pulmonary disease) could ...
Posted by Michael Wonder on 26 Jan 2026
Thousands could benefit from new take-at-home treatment for advanced prostate cancer
23 January 2026 - NICE recommends life-extending daily pill which offers hope for people who cannot take standard treatment. ...